Companies › Vaneltix Pharma
1 active drug program in 2 registered trials: 2 Phase 2; Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VNX001 Combination of alkalinized lidocaine HCl and heparin sodium | – | Phase 2 | Interstitial Cystitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05737121 | VNX001 | Phase 2 | Interstitial Cystitis | Genitourinary | Jun 2026 |
| NCT06394830 | VNX001 | Phase 2 | Interstitial Cystitis | Genitourinary | Jun 2026 |
No annotated target.
–
Kira Pharmacenticals (US) Veloxis Pharmaceuticals Juro Sciences Vifor Fresenius Medical Care Renal Pharma Tioga Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.